An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 [lacosamide] as Adjunctive Therapy in Patients With Partial Seizures.

Trial Profile

An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 [lacosamide] as Adjunctive Therapy in Patients With Partial Seizures.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 03 May 2014 Long-term results from a pooled analysis presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 10 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top